Table 1.
Synopsis of the cardiac effects of CgA and its derived peptides.
| Peptide | Tissue | Contractility/Relaxation | Heart rate | Vasoactivity | Doses | Adrenergic Stimulation | References |
|---|---|---|---|---|---|---|---|
| CgA | Ex vivo rat heart | Reduction | No changes | Vasodilation | 1 pM ÷ 4 nM | - | Pasqua et al., 2013 |
| VS1 | Ex vivo rat heart | Reduction | No changes | No changes | 11 ÷ 165nM | Non-competitive | Cerra et al., 2008 |
| Antagonism | |||||||
| rCGA1-64 | Ex vivo rat heart | Reduction | No changes | Vasodilation | 33 ÷ 165 nM | Non-competitive | Cerra et al., 2008 |
| Rat Papillary muscles | 10 ÷ 100 nM | Antagonism | |||||
| CST | Ex vivo rat heart | Reduction | No changes | Vasodilation | 11 ÷ 200 nM | Non-competitive | Angelone et al., 2008, 2012a |
| Antagonism | |||||||
| Serpinin | Ex vivo rat heart | Increase | No changes | No changes | 11 ÷ 165 nM | Beta-adrenergic like inotropim | Tota et al., 2012 |
| Rat Papillary muscles | 1 ÷ 33 nM |